beta

XFOR

X4 Pharmaceuticals Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

x4 pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. our oral, small molecule drug candidates inhibit the binding of chemokine cxcl12 to c-x-c receptor type 4 (cxcr4), a receptor-ligand pair that plays an essential role in normal immune surveillance. we are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. x4’s most advanced product candidate, x4p-001-rd, is in a phase 2/3 study in patients with whim syndrome, a rare genetic, primary immunodeficiency disease. x4p-001-io is currently under investigation in multiple phase 1/2 studies in refractory clear cell renal cell carcinoma (ccrcc) and melanoma. our third program, x4p-002, is in preclinical development and designed specifically for the t

Market Cap: 161 Million

Primary Exchange: NASDAQ

Website: http://www.x4pharma.com/

Shares Outstanding: 167 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.8132587599241112

Sector: Manufacturing

Industry: Biological Product (except Diagnostic) Manufacturing

Ethical Flags

Longest drawdown: 1038 trading days

From: 2019-03-21 To: 2024-03-07

Lowest Point:

X4 Pharma to fund no-cost genetic testing for rare immune deficiency disorder; shares up 3%

via: SeekingAlpha at 2019-06-12 06:35:20:000

Aimed at providing greater access to faster and earlier diagnosis for people who may have a genetic mutation linked to WHIM syndrome and severe congenital neutropenia, X4 Pharmaceuticals ( XFOR +2.6% ) will partner with Invitae ( NVTA -1.4% ) to offer free-of-charge genetic testin… read more...

X4 Pharma to fund no-cost genetic testing for rare immune deficiency disorder; shares up 3%

via: SeekingAlpha at 2019-06-12 06:35:20:000

Aimed at providing greater access to faster and earlier diagnosis for people who may have a genetic mutation linked to WHIM syndrome and severe congenital neutropenia, X4 Pharmaceuticals ( XFOR +2.6% ) will partner with Invitae ( NVTA -1.4% ) to offer free-of-charge genetic testin… read more...

X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease

via: Business Wire at 2019-06-12 04:30:00:000

Genetic testing to enable improved patient diagnoses and provide valuable disease-specific genetic insights for X4 clinical development of novel therapies X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeu… read more...

X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease

via: Business Wire at 2019-06-12 04:30:00:000

Genetic testing to enable improved patient diagnoses and provide valuable disease-specific genetic insights for X4 clinical development of novel therapies X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeu… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud